Senior Associate, Investments at Roivant Sciences

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, BiotechnologyIndustries

Requirements

Familiarity with the major scientific and medical aspects of drug development
Strong scientific and analytical skills
Exceptional attention to detail
Experience writing research reports and delivering presentations that integrate multiple data sources
Proficiency with MS Office suite, including functions and pivot tables (Word, Excel, and PowerPoint)
Experience using multiple pharmaceutical competitive intelligence databases
Excellent written and verbal communication skills
A minimum of two to three years of buy-side healthcare investing experience, primarily focused on therapeutics required
Bachelor’s degree required (preferably in science); MD or PhD strongly preferred

Responsibilities

Understand the broad biotech/pharmaceutical market landscape and clinical development process for marketing approval
Review, aggregate, analyze and monitor pharmaceutical development databases and market research reports
Help develop and grow a robust pipeline of targets by searching publicly available databases and online resources for novel drug development ideas
Create and maintain an internal database of potential acquisition candidates
Conduct in-depth scientific, clinical and market research and financial modeling to support recommendations
Help inform the investment thesis through rigorous modeling of potential commercial launch trajectories and revenue projections
Construct persuasive investment theses in the form of PowerPoint presentations and supporting Excel models
Communicate theses directly to senior management advocating for specific drug development projects
Partner with senior members of the Investment group to assist with all elements of transactions on new investments through closing, including due diligence, valuation, deal structuring, and negotiations

Skills

Biotech Market Analysis

Clinical Development

Pharmaceutical Databases

Market Research

Pipeline Development

Investment Analysis

Drug Acquisition

In-Licensing

Due Diligence

Business Development

Roivant Sciences

Develops biopharmaceuticals and RNA therapeutics

About Roivant Sciences

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

New York City, New YorkHeadquarters

2014Year Founded

$1,750.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Risks

Integration challenges from Dermavant acquisition may disrupt operations and delay development.

Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.

Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

Differentiation

Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.

The company builds Vants, nimble biotech firms, to enhance drug development efficiency.

Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Upsides

Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.

Strategic partnerships with Bayer and Roche accelerate drug development and market entry.

Increased investment from financial institutions highlights confidence in Roivant's growth potential.

Land your dream remote job 3x faster with AI

Try Jobo Free